Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinoma

Gisselbrecht, Christian; Calvo, Fabien; Mignot, L.; Pujade, Eric; Bouvry, M; Danne, O; Belpomme, D; Marty, M.

doi:10.1002/1097-0142(19830915)52:6<974::aid-cncr2820520607>3.0.co;2-#

Cited by 39 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, combination chemotherapy with 5‐FU, ADM and CDDP (FAP) has been reported to be useful in the treatment of advanced gastric cancer, esophageal cancer and other carcinomas 7,8 . Gisselbrecht et al .…”

Section: Discussionmentioning

confidence: 99%

“…Gisselbrecht et al . reported that the FAP regimen was administered to 21 patients with advanced esophageal cancer, 7 seven of them had an objective response (CR: 2, PR: 5), with no severe myelosuppression or nephrotoxicity observed.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, combination chemotherapy with 5-FU, ADM and CDDP (FAP) has been reported to be useful in the treatment of advanced gastric cancer, esophageal cancer and other carcinomas. 7,8 Gisselbrecht et al reported that the FAP regimen was administered to 21 patients with advanced esophageal cancer, 7 seven of them had an objective response (CR: 2, PR: 5), with no severe myelosuppression or nephrotoxicity observed.…”

Section: Discussionmentioning

confidence: 99%

“…6 Combination chemotherapy with 5-FU, adriamycin (ADM), and CDDP (FAP) has been reported to be useful in the treatment of advanced gastric cancer, esophageal cancer and other tumors. 7,8 Based on these findings, we planned a phase I and II study of the combination of NED, ADM, and 5-FU for treatment of previously untreated advanced esophageal cancer. The main purpose of the present study was to determine the maximum-tolerated dose (MTD), principal toxicity, and recommended dose (RD) for the phase II study.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer

Hirao

Fujitani

Tsujinaka

2004

Diseases of the Esophagus

View full text Add to dashboard Cite

This trial was conducted to determine the maximum-tolerated dose, principal toxicity, and recommended dose (RD) for the phase II study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) in patients with advanced esophageal cancer. Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function. The dose of NED, the key anticancer platinum complex drug, was increased from 60 to 70, and 80 mg/m(2) on day 1. ADM and 5-FU were administered at fixed doses (30 mg/m(2) on day 1, and 700 mg/m(2) on days 1-5). The dose-limiting toxicities of NED were neutropenia and severe diarrhea, and its maximum-tolerated dose and RD were 70 mg/m(2) and 60 mg/m(2), respectively. There were four responders among the six patients administered the RD. The present study thus revealed combination chemotherapy with NED, ADM, and 5-FU to be active and well-tolerated and to warrant phase II study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer

Hirao

Fujitani

Tsujinaka

2004

Diseases of the Esophagus

View full text Add to dashboard Cite

show abstract

“…Therefore, the JCOG concluded that standard-dosage FP is superior to daily low-dosage FP [22]. Concerning the next regimen of standard FP for the neoadjuvant setting or for the non-surgical setting, several regimens such as DFC and FAP are being investigated now in Japan [23][24][25][26][27][28].…”

Section: Chemotherapy Regimenmentioning

confidence: 99%

The Japan Esophageal Society Consensus Meeting 2010

Fujita

Kitagawa

2011

Esophagus

View full text Add to dashboard Cite

The consensus meeting was held at the 64th Annual Meeting of the Japan Esophageal Society (JES) in 2010. The majority of the 150 participants were surgeons with a license as a specialist in esophageal surgery or as a certified esophagologist authorized by the JES working in a university hospital or cancer center. Using the answer pad system, each participant chose one answer among three to five answers to a total of 32 questions. Concerning the Japanese Classification of Esophageal Cancer, the majority supported dividing T4 into T4a and T4b, to classify the N category based on a combination of the spread and the number of lymph nodes with metastasis, and to maintain the anatomical staging and the same staging systems for squamous cell carcinoma and adenocarcinoma. Concerning perioperative management, the majority supported no intubation or overnight intubation for respiratory support, the early start of tube feeding within POD 1-3, and the start of peroral intake on around POD 7 after esophagography. Concerning treatment strategy, the majority supported endoscopic treatment for T1a-EP/LPM cancer and esophagectomy for T1b-SM2/SM3 cancer. There was no consensus on the treatment for T1a-MM/T1b-SM1 cancer. They supported neoadjuvant CT followed by esophagectomy for stage II-III cancer, and they supported dCRT as necessary with salvage surgery for cT4 cancer. The JES Consensus Meeting 2010 clarified the motion for the next revision of the Japanese Classification and also determined the policy for the treatment strategy in practice for esophageal cancers.

show abstract

Anterior chemotherapy in esophageal cancer

Advani

Saikia

Swaroop

et al. 1985

Cancer

View full text Add to dashboard Cite

Front loading chemotherapy using methotrexate (200 mg/m2) alone or methotrexate (200 mg/m2) with cisplatin (20 mg/m2 daily for 5 days) was used in epidermoid carcinoma of esophagus. Evaluation after two courses showed objective response of 50% or greater in 48% of patients with methotrexate alone. Response rate was increased to 76.2% with addition of cisplatin to methotrexate. Small lesions (less than 10 cm) showed better response as compared to advanced cases. Therapy was generally well tolerated and good palliation was obtained even after the first course. Postchemotherpy treatment either with surgery or radiotherapy was tolerated without any major complications. The data confirm the short-term usefulness of initial chemotherapy with methotrexate and cisplatin in esophageal cancer. Results of prolonged follow-up will help to evaluate the role of front loading chemotherapy on long-term survival.

show abstract

Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinoma

Cited by 39 publications

References 7 publications

Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer

Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer

The Japan Esophageal Society Consensus Meeting 2010

Anterior chemotherapy in esophageal cancer

Contact Info

Product

Resources

About